OOIR: Observatory of International Research

Papers

(The median citation count of Translational Neurodegeneration is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes	1196
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential	178
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration	169
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond	111
Advances in the development of new biomarkers for Alzheimer’s disease	101
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases	84
COVID-19 and Alzheimer’s disease: how one crisis worsens the other	78
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis	59
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases	57
Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy	56
Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study	55
TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut	54
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review	53
Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications	52
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease	48
Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease	47
Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies	43
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	43
Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer’s disease	40
Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation	38
Circadian disruption and sleep disorders in neurodegeneration	37
Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases	37
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms	35
Mitochondrial links between brain aging and Alzheimer’s disease	34
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	34

Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases	33
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?	33
Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases	32
Prodromal Parkinson's disease: hype or hope for disease-modification trials?	32
The effects of transcranial direct current stimulation on gait in patients with Parkinson’s disease: a systematic review	31
Parkinson’s disease–associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy	30
Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients	29
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	29
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease	29
Recent advances on the molecular mechanisms of exercise-induced improvements of cognitive dysfunction	29
Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system	28
An old weapon with a new function: PIWI-interacting RNAs in neurodegenerative diseases	27
Role of dopamine in the pathophysiology of Parkinson’s disease	27
Translational Neurodegeneration in the era of fast growing international brain research	27
Effects of transcranial ultrasound stimulation pulsed at 40 Hz on Aβ plaques and brain rhythms in 5×FAD mice	27
New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis	26
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial	26
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials	26
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals	26
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease	25
The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders	25
Ecto-GPR37: a potential biomarker for Parkinson’s disease	25
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	25
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock	25
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	24
Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis	24
Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in Drosophila	22
Language training for oral and written naming impairment in primary progressive aphasia: a review	22
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model	22
Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms	22
Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta	22
Early life adversity as a risk factor for cognitive impairment and Alzheimer’s disease	22
Recommendations for the diagnosis and treatment of paroxysmal kinesigenic dyskinesia: an expert consensus in China	21
Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model	21
Animal models of Parkinson’s disease: bridging the gap between disease hallmarks and research questions	21
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease	21
Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise	20
Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	20
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	20
Clinical and genetic characterization of a large cohort of patients with Wilson’s disease in China	20
Optimization of cerebral organoids: a more qualified model for Alzheimer’s disease research	19
Targeting neuroplasticity in patients with neurodegenerative diseases using brain stimulation techniques	19
Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1	17
Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients	17
The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population	17
Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules	17
Myelin repair in Alzheimer’s disease: a review of biological pathways and potential therapeutics	17
Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer’s disease	17
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	16
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases	16

Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis	16
Genetic heterogeneity on sleep disorders in Parkinson’s disease: a systematic review and meta-analysis	16
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease	16
Pathophysiological significance of increased α-synuclein deposition in sympathetic nerves in Parkinson’s disease: a post-mortem observational study	15
Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis	15
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	15
Microtubule acetylation dyshomeostasis in Parkinson’s disease	15
Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases	15
Research progress on the role of extracellular vesicles in neurodegenerative diseases	15
Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine	15
Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson’s disease and multiple system atrophy	15
Parkinson’s disease and translational research	14
Disruption of the white matter structural network and its correlation with baseline progression rate in patients with sporadic amyotrophic lateral sclerosis	14
EEG/ERP evidence of possible hyperexcitability in older adults with elevated beta-amyloid	13
Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease	13
A natural history comparison of SOD1-mutant patients with amyotrophic lateral sclerosis between Chinese and German populations	13
Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia	13
p85S6K sustains synaptic GluA1 to ameliorate cognitive deficits in Alzheimer’s disease	13
Multi-mechanical waves against Alzheimer’s disease pathology: a systematic review	13
Genetic spectrum and clinical features in a cohort of Chinese patients with autosomal recessive cerebellar ataxias	13
A review of brain imaging biomarker genomics in Alzheimer’s disease: implementation and perspectives	12
Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment	12
Differential seeding and propagating efficiency of α-synuclein strains generated in different conditions	12
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	12
Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer’s disease-related pathologies in a senescence-accelerated mouse model	12
Association of variants in the KIF1A gene with amyotrophic lateral sclerosis	11
Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models	11
N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology	11
Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: removing axonal debris	10
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	10
NMDAR-dependent somatic potentiation of synaptic inputs is correlated with β amyloid-mediated neuronal hyperactivity	10
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases	10
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	10
Effectiveness and mechanisms of adipose-derived stem cell therapy in animal models of Parkinson’s disease: a systematic review and meta-analysis	10
Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease	9
α-Synuclein arginylation in the human brain	9
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	9
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	9
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	9
The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing	9
APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease	9
An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers	9
Axonal degeneration in the anterior insular cortex is associated with Alzheimer’s co-pathology in Parkinson’s disease and dementia with Lewy bodies	9
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	9
Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy	9